Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Acinetobacter baumannii Infections - A Systematic Review

Author(s): Hemasri Velmurugan, Sajitha Venkatesan, Hadush Negash Meles, Krishnapriya Neelambaram and Pugazhenthan Thangaraju*

Volume 24, Issue 6, 2024

Published on: 22 January, 2024

Article ID: e220124225835 Pages: 7

DOI: 10.2174/0118715265276432231217192054

Price: $65

Abstract

Background: Sulbactam-durlobactam (SUL-DUR) has been tested in vitro for its ability to generate resistance in clinical isolates of Acinetobacter species. According to prior studies, combining durlobactam with sulbactam causes sulbactam-resistant isolates to become more active and revert to susceptibility. We aimed to conduct a systematic review of the in vitro activity of SUL-DUR on A. baumannii (Ab) isolates, including carbapenem-resistant A. baumannii (CRAb), to provide an overview for physicians dealing with Ab infections.

Methods: The following keywords were searched in the PubMed, Google Scholar, and EMBASE databases to look for eligible original works that have been published without restrictions till June 30, 2023: A. baumannii and sulbactam-durlobactam, SUL-DUR, durlobactam, and sulbactam-ETX2514. We also searched clinicaltrials.gov and the Clinical Trials Registry of India (CTRI) for clinical trials involving sulbactamdurlobactam and Acinetobacter.

Results: There were a total of 852 abstracts found. Among them, 633 articles with titles, abstracts, and keywords were reviewed, and 574 articles were removed after the initial screening. A total of 59 full-text eligible articles were evaluated, and 51 of them were eliminated because they did not satisfy the criteria set for inclusion. The full texts of the final 8 in vitro studies on A. baumanii and sulbactam/durlobactam were further evaluated. There were 5 trials on A. baumanii and sulbactam/durlobactam found on clinicaltrials.gov and the Clinical Trial Registry of India (CTRI).

Conclusion: The findings from the studies show that SUL-DUR might be a successful therapeutic option for multidrug-resistant-Ab infections. Future clinical trials will be required to validate the possibility of using this combination to treat multidrug-resistant A. baumannii infections.

Graphical Abstract

[1]
Ayoub Moubareck C, Hammoudi Halat D. Insights into acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics 2020; 9(3): 119.
[http://dx.doi.org/10.3390/antibiotics9030119]
[2]
Kittinger C, Kirschner A, Lipp M. Antibiotic Resistance of Acinetobacter spp. Isolates from the River Danube: Susceptibility Stays High. Int J Environ Res Public Health 2017; 15(1): 52.
[http://dx.doi.org/10.3390/ijerph15010052]
[3]
Lee CR, Lee JH, Park M. Biology of acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 2017; 7: 55.
[http://dx.doi.org/10.3389/fcimb.2017.00055]
[4]
Zarrilli R, Bagattini M, Migliaccio A, Esposito EP, Triassi M. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Italy. Ann Ig 2021; 33(5): 401-9.
[PMID: 33270079]
[5]
Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist 2018; 11: 1249-60.
[http://dx.doi.org/10.2147/IDR.S166750] [PMID: 30174448]
[6]
Pormohammad A, Mehdinejadiani K, Gholizadeh P, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microb Pathog 2020; 139: 103887.
[http://dx.doi.org/10.1016/j.micpath.2019.103887] [PMID: 31765766]
[7]
McLeod SM, Shapiro AB, Moussa SH, et al. Frequency and mechanism of spontaneous resistance to sulbactam combined with the novel β-lactamase inhibitor ETX2514 in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2018; 62(2): e01576-17.
[http://dx.doi.org/10.1128/AAC.01576-17] [PMID: 29133555]
[8]
Barnes MD, Kumar V, Bethel CR, et al. Targeting multidrug-resistant acinetobacter spp.: Sulbactam and the diazabicyclooctenone β-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio 2019; 10(2): e00159-19.
[9]
O’Donnell JP, Bhavnani SM. The pharmacokinetics/pharmacodynamic relationship of durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versusacinetobacter baumannii-calcoaceticus complex. Clin Infect Dis 2023; 76 (Suppl. 2): S202-9.
[http://dx.doi.org/10.1093/cid/ciad096] [PMID: 37125469]
[10]
Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59(3): 1680-9.
[http://dx.doi.org/10.1128/AAC.04808-14] [PMID: 25561334]
[11]
Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA. Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam. Front Microbiol 2021; 1953
[http://dx.doi.org/10.3389/fmicb.2021.709974 ]
[12]
Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021; 10(3): 373.
[http://dx.doi.org/10.3390/pathogens10030373]
[13]
Granata G, Taglietti F, Schiavone F, Petrosillo N. Durlobactam in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review. J Clin Med 2022; 11(12): 3528.
[http://dx.doi.org/10.3390/jcm11123258]
[14]
Durand-Réville TF, Guler S, Comita-Prevoir J, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2017; 2(9): 17104.
[http://dx.doi.org/10.1038/nmicrobiol.2017.104] [PMID: 28665414]
[15]
U.S National Library of Medicine. Clinical trials 2023. Available from: https://www.clinicaltrials.gov/ (Assessed on 25, June 2023)
[16]
Clinical Trial Registry of India. 2023. Available from: https://ctri.nic.in/Clinicaltrials/login.php (Assessed on 25, June 2023)
[17]
Papp-Wallace KM, McLeod SM, Miller AA. Durlobactam, a broad-spectrum serine β-lactamase inhibitor, restores sulbactam activity against acinetobacter species. Clin Infect Dis 2023; 76 (Suppl. 2): S194-201.
[http://dx.doi.org/10.1093/cid/ciad095] [PMID: 37125470]
[18]
Findlay J, Poirel L, Bouvier M, Nordmann P. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist 2022; 30: 445-50.
[http://dx.doi.org/10.1016/j.jgar.2022.05.011] [PMID: 35618210]
[19]
Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii - calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66(9): e00781-22.
[http://dx.doi.org/10.1128/aac.00781-22] [PMID: 36005804]
[20]
Petropoulou D, Siopi M, Vourli S, Pournaras S. Activity of sulbactam-durlobactam and comparators against a national collection of carbapenem-resistant Acinetobacter baumannii isolates from greece. Front Cell Infect Microbiol 2022; 11: 814530.
[http://dx.doi.org/10.3389/fcimb.2021.814530]
[21]
Segatore B, Piccirilli A, Cherubini S. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: A multicentre report from italy. Antibiotics 2022; 11(8): 1126.
[http://dx.doi.org/10.3390/antibiotics11081136]
[22]
McLeod SM, Moussa SH, Hackel MA, Miller AA. In vitro activity of sulbactam-durlobactam against acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017. Antimicrob Agents Chemother 2020; 64(4): e02534-19.
[http://dx.doi.org/10.1128/AAC.02534-19]
[23]
Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2020; 75(9): 2616-21.
[http://dx.doi.org/10.1093/jac/dkaa208] [PMID: 32516359]
[24]
Yang Q, Xu Y, Jia P, et al. In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China. J Antimicrob Chemother 2020; 75(7): 1833-9.
[http://dx.doi.org/10.1093/jac/dkaa119] [PMID: 32306049]
[25]
Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. J Clin Microbiol 2021; 59(12): e00213-21.
[http://dx.doi.org/10.1128/JCM.00213-21 ] [PMID: 34550809]
[26]
U.S National Library of Medicine. Evaluation of the safety, tolerability and pharmacokinetics of intravenous ETX2514 administered in healthy subjects. NCT02971423, 2023.
[27]
U.S National Library of Medicine. Study to evaluate the efficacy and safety of intravenous sulbactam-ETX2514 in the treatment of patients with infections caused by Acinetobacter Baumanniicalcoaceticus complex (ATTACK). NCT03894046, 2023.
[28]
U.S National Library of Medicine Evaluation of the pharmacokinetics, safety, and tolerability of intravenous ETX2514 and sulbactam administered concurrently to subjects with various degrees of renal impairment and healthy matched control subjects. NCT03310463, 2023.
[29]
U.S National Library of Medicine Study to determine and compare plasma and intrapulmonary concentrations of ETX2514 and sulbactam in healthy subjects. NCT03303924, 2023.
[30]
Clinical Trial Registry of India. 2023. Available from: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35331&EncHid=&userName=Acinetobacter (Assessed on 25, June 2023)
[31]
Lickliter JD, Lawrence K, O’Donnell J, Isaacs R. Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2020; 64(7): e00071-20.
[http://dx.doi.org/10.1128/AAC.00071-20]
[32]
Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23: S1437.
[http://dx.doi.org/10.1016/S1473-3099(23)00184-6]
[33]
O’Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R. Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects. Antimicrob Agents Chemother 2019; 63(9): e00794-19.
[http://dx.doi.org/10.1128/AAC.00794-19]
[34]
Rodvold KA, Gotfried MH, Isaacs RD, O’Donnell JP, Stone E. Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects. Antimicrob Agents Chemother 2018; 62(11): e01089-18.
[http://dx.doi.org/10.1128/AAC.01089-18 ] [PMID: 30126953]
[35]
Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ. Acinetobacter baumannii resistance: A real challenge for clinicians. Antibiotics 2020; 9(4): 205.
[http://dx.doi.org/10.3390/antibiotics9040205]
[36]
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008; 21(3): 538-82.
[http://dx.doi.org/10.1128/CMR.00058-07] [PMID: 18625687]
[37]
Chusri S, Chongsuvivatwong V, Rivera JI, et al. Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob Agents Chemother 2014; 58(7): 4172-9.
[http://dx.doi.org/10.1128/AAC.02992-14] [PMID: 24820079]
[38]
Chang WN, Lu CH, Huang CR, Chuang YC. Community-acquired Acinetobacter meningitis in adults. Infection 2000; 28(6): 395-7.
[http://dx.doi.org/10.1007/s150100070013] [PMID: 11139162]
[39]
World Health Organization Global Priority List of Antibiotic- Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 (Accessed on 1 August 2022)
[40]
Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(1): 1-12.
[http://dx.doi.org/10.1086/595011] [PMID: 19035777]
[41]
Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Health 2014; 2014(1): 147.
[http://dx.doi.org/10.1093/emph/eou024] [PMID: 25355275]
[42]
(a) Brown S, Amyes S. OXA β-lactamases in Acinetobacter: The story so far. J Antimicrob Chemother 2006; 57(1): 1-3.;
(b) Cai Y, Chai D. Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67(7): 1607-15.
[PMID: 22441575]
[43]
Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V. In vitro activities of colistin and ampicillin/sulbactam against acinetobacter baumannii. J Med Assoc Thailand 2011; 94: S95-S100.
[44]
Wadl M, Heckenbach K, Noll I, et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four german university hospitals, 2002-2006. Infection 2010; 38(1): 47-51.
[http://dx.doi.org/10.1007/s15010-009-9225-x] [PMID: 20108161]
[45]
Sengstock DM, Thyagarajan R, Apalara J, Mira A, Chopra T, Kaye KS. Multidrug-resistant Acinetobacter baumannii: An emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010; 50(12): 1611-6.
[http://dx.doi.org/10.1086/652759] [PMID: 20462357]
[46]
Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of acinetobacter infections: A century of challenges. Clin Microbiol Rev 2017; 30(1): 409-47.
[http://dx.doi.org/10.1128/CMR.00058-16] [PMID: 27974412]
[47]
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21(2): 226-40.
[http://dx.doi.org/10.1016/S1473-3099(20)30796-9] [PMID: 33058795]
[48]
Principe L, Di Bella S, Conti J, et al. Acinetobacter baumannii resistance to sulbactam/durlobactam: A Systematic review. Antibiotics 2022; 11(12): 1793.
[http://dx.doi.org/10.3390/antibiotics11121793] [PMID: 36551450]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy